Phase-specific signatures of wound fibroblasts and matrix patterns define cancer-associated fibroblast subtypes.


Journal

Matrix biology : journal of the International Society for Matrix Biology
ISSN: 1569-1802
Titre abrégé: Matrix Biol
Pays: Netherlands
ID NLM: 9432592

Informations de publication

Date de publication:
05 2023
Historique:
received: 18 11 2022
revised: 23 01 2023
accepted: 02 03 2023
medline: 5 5 2023
pubmed: 14 3 2023
entrez: 13 3 2023
Statut: ppublish

Résumé

Healing wounds and cancers present remarkable cellular and molecular parallels, but the specific roles of the healing phases are largely unknown. We developed a bioinformatics pipeline to identify genes and pathways that define distinct phases across the time-course of healing. Their comparison to cancer transcriptomes revealed that a resolution phase wound signature is associated with increased severity in skin cancer and enriches for extracellular matrix-related pathways. Comparisons of transcriptomes of early- and late-phase wound fibroblasts vs skin cancer-associated fibroblasts (CAFs) identified an "early wound" CAF subtype, which localizes to the inner tumor stroma and expresses collagen-related genes that are controlled by the RUNX2 transcription factor. A "late wound" CAF subtype localizes to the outer tumor stroma and expresses elastin-related genes. Matrix imaging of primary melanoma tissue microarrays validated these matrix signatures and identified collagen- vs elastin-rich niches within the tumor microenvironment, whose spatial organization predicts survival and recurrence. These results identify wound-regulated genes and matrix patterns with prognostic potential in skin cancer.

Identifiants

pubmed: 36914141
pii: S0945-053X(23)00025-2
doi: 10.1016/j.matbio.2023.03.003
pii:
doi:

Substances chimiques

Elastin 9007-58-3
Collagen 9007-34-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-56

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest RD has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME, all outside of the submitted work. No other authors have potential competing interests to declare.

Auteurs

Mateusz S Wietecha (MS)

Institute of Molecular Health Sciences, Department of Biology, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland; Present address: Department of Oral Biology, College of Dentistry, University of Illinois Chicago, 801 S. Paulina St., Chicago, IL 60612, USA. Electronic address: mwietec2@uic.edu.

David Lauenstein (D)

Institute of Molecular Health Sciences, Department of Biology, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland.

Michael Cangkrama (M)

Institute of Molecular Health Sciences, Department of Biology, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland.

Sybille Seiler (S)

Institute of Molecular Health Sciences, Department of Biology, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland.

Juyoung Jin (J)

Institute of Molecular Health Sciences, Department of Biology, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland.

Andreas Goppelt (A)

Ottobock SE & Co. KGaA; 37115 Duderstadt, Germany.

Manfred Claassen (M)

Department of Medicine, Department of Computer Science, Eberhard Karls University, 72076 Tübingen, Germany.

Mitchell P Levesque (MP)

Department of Dermatology, University of Zürich Hospital, 8952 Schlieren, Switzerland.

Reinhard Dummer (R)

Department of Dermatology, University of Zürich Hospital, 8952 Schlieren, Switzerland.

Sabine Werner (S)

Institute of Molecular Health Sciences, Department of Biology, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland. Electronic address: sabine.werner@biol.ethz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH